LAG3 and neoplasm: It is aiming to compare the efficacy of a fixed-dose combination of relatlimab [lymphocyte-activation gene 3 (LAG-3)] antagonist and nivolumab versus nivolumab monotherapy in patients diagnosed with stage III or IV melanoma who have undergone a complete removal of their tumor(s).